Candel Therapeutics is a developer of cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster. Candel Therapeutics was founded in 1999 by Estuardo Aguilar-Cordova and is headquartered in Needham, MA.
Candel Therapeutics is privately held company and is not publicly traded, therefor investing in Candel Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.
To determine the value of your Candel Therapeutics shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Candel Therapeutics shares. You can also learn more about how to sell your private shares before getting started.
Yes, you can seek to sell shares in Candel Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.